Core Insights - BostonGene and Unilever have formed a strategic partnership to leverage AI and multiomics research for consumer innovation, aiming to inspire the next generation of science-based product development [1] - The collaboration will utilize BostonGene's advanced AI capabilities and omnimodal data integration alongside Unilever's scientific expertise to explore biological differences and generate actionable insights for product innovation [1] Company Overview - BostonGene specializes in AI-driven solutions for tumor and immune biology, integrating genomic, transcriptomic, and immune data with clinical outcomes to enhance drug development and patient care [1] - Unilever is a leading global supplier of consumer goods, with sales of €50.5 billion in 2025 and products used by 3.7 billion people daily [1] Partnership Objectives - The partnership aims to apply advanced AI and multiomics approaches to uncover insights that will drive innovative product development for Unilever's consumer base [1] - Unilever's investment in cutting-edge science and technology is intended to maintain its competitive edge in scientific innovation [1] Future Implications - The collaboration is expected to extend BostonGene's foundation model beyond oncology into broader areas of human biology, potentially accelerating discoveries that influence consumer-focused science [1]

Core Insights - Illumina has announced significant breakthroughs in oncology through the use of its multiomics solutions, including spatial transcriptomics, 5-base sequencing, and proteomics technologies, which enhance precision diagnostics and targeted therapeutics development [1][2] Group 1: Multiomics Solutions - The integration of multiple omic insights provides unprecedented biological depth, enabling researchers to achieve breakthroughs in oncology and pharmacogenomics [1] - Illumina's Connected Multiomics platform streamlines multimodal data analysis, facilitating a deeper understanding of tumor microenvironments [1] Group 2: Spatial Technology - Illumina Spatial Technology has been utilized to decode complex tissues, such as the human lymphatic system, improving cancer diagnosis and prognosis [1] - Research using Illumina Spatial Technology has produced the first whole transcriptome spatial datasets for human lymphatic collector vessels, aiding in the understanding of lymphatic vessel functions [1] Group 3: 5-Base Sequencing - The 5-base solution has been applied in pediatric kidney cancer research, allowing for simultaneous genomic and methylation profiling, which enhances diagnostic accuracy [1][2] - This solution has successfully identified cases of rhabdoid tumors that were missed by conventional genomic methods, indicating its potential for improving patient outcomes [1] Group 4: Ovarian Cancer Research - Illumina's technologies have enabled researchers to differentiate between cancerous and benign tumor types in ovarian cancer, creating a multiomic framework for future research [2] - The combination of 5-base sequencing and Illumina Protein Prep has led to the identification of novel gene sets and pathways in ovarian cancer, opening new avenues for biomarker and drug development [2] Group 5: Advancements in Diagnostics - The integration of multiomics analytics provides deeper insights into cancer mechanisms and tumor heterogeneity, which can lead to the identification of new therapeutic targets [2] - Illumina's Connected Multiomics accelerates the sample-to-answer pipeline, overcoming challenges associated with isolated assays [2]

Hi, welcome to Arc Invest's Big Ideas 2026 deep dive. I'm Brett Winton, the chief futurist, and I'm going to start right on slide four, which is titled the great acceleration. The um the core thesis both in this section and across the entire deck is that AI is the central dynamo, the spinning wheel of magic that is accelerating you know all the five major innovation platforms that we focus on and igniting a new era of um macroeconomic growth.Um so the five major innovation platforms AI, public blockchains, ...

Join us as the ARK team takes a deep dive into our Big Ideas 2026 research report. To follow along, make sure to download the full report at https://www.ark-invest.com/big-ideas-2026 Key Sections: 00:00:00 The Great Acceleration 00:16:13 AI Infrastructure 00:27:56 The AI Consumer Operating System 00:38:23 AI Productivity 00:43:18 Bitcoin 00:55:29 Tokenized Assets 01:00:23 Decentralized Finance Applications 01:04:40 Multiomics 01:18:06 Reusable Rockets 01:22:45 Robotics 01:32:54 Distributed Energy 01:37:47 A ...

Q4 2025 Earnings Presentation February 5, 2026 © 2026 Illumina, Inc. All rights reserved. Cautionary Notes Year-over-year (YoY) denotes a comparison against the same quarter of the previous fiscal year, while quarter-over-quarter (QoQ) or "sequential" denotes a comparison against the previous fiscal quarter. In addition, all references to China refer to our Greater China Region, which also includes Taiwan and Hong Kong. © 2026 Illumina, Inc. All rights reserved. 2 RGB: 229, 96, 0 RGB: 228, 189, 255 RGB: 255 ...

Core Insights - Illumina has completed the acquisition of SomaLogic, enhancing its capabilities in proteomics and multiomics, which will facilitate faster drug discovery and improve healthcare outcomes [1][2][5] Group 1: Acquisition Details - The acquisition was finalized for $350 million in cash, with potential additional payments of up to $75 million based on performance milestones [6] - This acquisition builds on a prior partnership that began in late 2021, aimed at integrating SomaLogic's technology with Illumina's high-throughput NGS platforms [5] Group 2: Strategic Implications - The combination of SomaLogic's proteomics technology with Illumina's existing innovations is expected to provide scalable insights across genomics and proteomics, enhancing customer outcomes [2][3] - Illumina aims to leverage this acquisition to strengthen its position in the growing proteomics market, thereby complementing its high-throughput sequencing business [3] Group 3: Product Integration and Support - Illumina will ensure continuity of products and services as SomaLogic's portfolio is integrated into its offerings, maintaining support for existing customers [4][5] - The integration will allow customers to generate rich multiomic datasets, utilizing a combination of SomaLogic's and Illumina's technologies [2][5]

RT ARK Invest (@ARKInvest)Chronological age ≠ biological age. The multiomics section of Big Ideas 2026 explores how aging and mortality risk are being measured with increasing precision + the economic value of extending healthy human life.@Shea_ARK's thread below⬇️Full report: https://t.co/Uw1o20VSMc ...

Core Insights - Ark Invest has released its 10th annual "Big Ideas" list for 2026, highlighting key themes and investment opportunities following a strong performance in 2025, where its ETFs outperformed the S&P 500 [1][2] Group 1: Thematic Trends - "The Great Acceleration" is identified as a central theme for 2026, impacting various technologies such as AI, public blockchains, robotics, energy storage, and multiomics, which is expected to drive significant GDP growth [2][3] - Capital investment in disruptive innovation platforms could contribute an additional 1.9 percentage points to annualized real GDP growth during this decade, focusing on innovations like robotaxis and AI agents [3] Group 2: Investment Opportunities in ETFs - Ark's thematic ETFs are aligned with the Big Ideas for 2026, with U.S. ETFs and public companies holding 12% of total Bitcoin supply, and Bitcoin ETF balances increasing by 19.7% in 2025 [4] - The Ark Autonomous Technology & Robotics ETF and Ark Space & Defense Innovation ETF were the top performers among Ark's ETFs, achieving gains of 49.8% and 49.2% respectively in 2025 [4] Group 3: Key Companies and Stocks - Several publicly traded companies are highlighted as key players in the 2026 themes, including Coinbase Global, Circle Internet Group, and Robinhood Markets for the tokenized assets theme [8] - For the Multiomics theme, notable stocks include Illumina Inc, CRISPR Therapeutics, and 10x Genomics, which are expected to drive advancements in healthcare [9] - Waymo, owned by Alphabet Inc, is recognized as a disruptor in the autonomous vehicles sector, impacting competitors like Uber and Lyft [10] - Tesla Inc, while not frequently mentioned, is central to multiple Big Ideas, including autonomous vehicles and distributed energy, and remains a significant holding in Ark's portfolios [11]

44th Annual J.P. Morgan Healthcare Conference Jacob Thaysen, PhD Chief Executive Officer January 13, 2026 © 2026 Illumina, Inc. All rights reserved. © 2026 Illumina, Inc. All rights reserved. Cautionary Notes On Forward Looking Statements This release may contain forward-looking statements that involve risks and uncertainties. Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are: J.P. Morgan Healthc ...

Core Insights - Illumina, Inc. has launched Illumina Connected Multiomics, a cloud-based platform for analyzing and visualizing multiomic and multimodal biological data at scale, which was developed with input from 40 early access users [1][5] - The launch is expected to enhance the user experience across Illumina's software portfolio and is aimed at advancing precision health discovery and drug development [2][3] Company Performance - Following the announcement of Connected Multiomics, Illumina's shares increased by 4.1%, closing at $147.11, indicating a positive market reaction [3][9] - Illumina currently has a market capitalization of $21.56 billion and an earnings yield of 3.6%, which is significantly better than the industry's -16.4% yield [4] Product Features - Connected Multiomics can aggregate thousands of multiomic samples from both Illumina and third-party assays, providing reproducible results and interactive visualizations in a single cloud-based environment [5] - The platform includes AI-enabled variant interpretation to enhance the analysis process by identifying biologically meaningful signals earlier [5][6] Industry Outlook - The global multiomics market was valued at $2.7 billion in 2024 and is projected to grow at a CAGR of 15.3% by 2033, driven by increasing demand for single-cell multiomics and advancements in omics technologies [10] - Key components such as genomics, proteomics, metabolomics, and transcriptomics are seeing increased adoption in healthcare applications, which bodes well for Illumina's growth [10] Stock Performance - Over the past three months, Illumina's shares have risen by 48.5%, outperforming the industry growth of 12.7% [12]